Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus

Sandro Vento, Francesca Cainelli, Franca Mirandola, Lucio Cosco, Giovanni Di Perri, Maurizio Solbiati, Teresa Ferraro, Ercole Concia

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

Background. Fulminant hepatitis on withdrawal of chemotherapy has been described in chronic hepatitis B virus infection, but not in hepatitis C virus (HCV) infection. The relation between HCV and immune response to this virus, and disease severity, has not been examined. We present two patients with HCV who developed fulminant liver failure after chemotherapy was stopped. Patients and findings. Two patients with chronic HCV infection and malignant lymphoma received chemotherapy (cyclophosphamide, adriamycin, vincristine, bleomycin, etoposide, and prednisolone in patient 1; doxorubicin, bleomycin, vinblastine, and dacarbazine in patient 2), on withdrawal of which both developed fulminant hepatitis. Alanine aminotransferase (ALT) concentrations were greatly raised (6030 and 3870 IU/L in patients 1 and 2, respectively), and serum HCV-RNA was low in both patients when severe disease developed (102 genome equivalents per mL). Patient 1 died, and necropsy showed massive liver necrosis. Interpretation. The findings suggest an immune-mediated mechanism for hepatocyte damage in HCV infection. Careful monitoring of ALT concentrations is necessary in such patients during and after chemotherapy.

Original languageEnglish
Pages (from-to)92-93
Number of pages2
JournalLancet
Volume347
Issue number8994
DOIs
Publication statusPublished - Jan 13 1996

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus'. Together they form a unique fingerprint.

  • Cite this

    Vento, S., Cainelli, F., Mirandola, F., Cosco, L., Di Perri, G., Solbiati, M., Ferraro, T., & Concia, E. (1996). Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet, 347(8994), 92-93. https://doi.org/10.1016/S0140-6736(96)90212-3